Associate editor: B. McDermottStatins and cardioprotection — More than just lipid lowering?
Introduction
Coronary heart disease (CHD) is the leading cause of morbidity and mortality worldwide. HMG-CoA reductase inhibitors (henceforth referred to as ‘statins’) have become standard medical therapy in the armamentarium available for the prevention and treatment of cardiovascular disease. Large randomised controlled clinical trials have established their role as effective medical therapy for the primary (Shepherd et al., 1995, Downs et al., 1998) and secondary (Pedersen et al., 2005, Heart Protection Study Collaborative Group, 2002) prevention of cardiovascular events. HMG-CoA reductase inhibitors competitively inhibit the conversion of acetyl coenzyme A and acetoacetyl coenzyme A to mevalonate in the formation of cholesterol and prevent the formation of the isoprenoids (Istvan, 2002) (see Fig. 1). Statins were first developed in order to lower total serum cholesterol and improve the lipid profile but have subsequently been shown to exert a variety of beneficial, ‘pleiotropic’ effects, particularly relevant to cardiovascular disease, including improved endothelial function, reduced oxidative stress, less platelet adhesion, and atherosclerotic plaque stabilisation (Ray & Cannon, 2005).
It is well-established that statin therapy offers widespread beneficial effects on the cardiovascular system through both its lipid lowering and non-lipid lowering effects described above. However, in this article, we will focus on a less appreciated non-lipid lowering effect of statin therapy, namely its potential to directly protect the myocardium from the detrimental effects of acute ischaemia–reperfusion injury, a feature which has been widely documented in the experimental literature. The mechanisms underlying this cardioprotective effect and the implications for clinical therapy of patients with CHD will be covered.
Section snippets
Experimental cardioprotection using statin therapy
In the late 1990s, the finding that statin therapy was beneficial in terms of improving cardiovascular outcomes resulted in a search for the mechanisms underlying this cardioprotective effect. Using experimental animal models of acute myocardial ischaemia–reperfusion injury, it is possible to examine the effects of statin therapy at different time-points in the course of the acute ischaemia–reperfusion insult. In this section we review the experimental evidence for acute cardioprotection
Potential mechanisms underlying statin-induced cardioprotection
Nitric oxide has been implicated as a crucial signalling molecule in the mechanism of cardioprotection and the other pleiotropic effects of statin therapy (Fig. 2). Experimental studies have demonstrated that statins stabilise eNOS mRNA, upregulate and activate eNOS and increase NO production (Laufs et al., 1997, Laufs et al., 1998, Scalia et al., 2001). The mechanism through which statins actually activate the nitric oxide signalling pathway is still the subject of investigation but it may be
Clinical cardioprotection using statin therapy
The experimental animal studies suggest that statin therapy has the ability to protect the myocardium against the detrimental effects of acute ischaemia–reperfusion injury irrespective of whether it is administered prior to the index ischaemic event or at the onset of myocardial reperfusion. As such it could be argued that statin therapy may theoretically confer cardioprotection in a range of clinical settings including those in which the index ischaemic event can be readily anticipated such as
Conclusion
Statins are established as playing a major role in cardiovascular disease in almost all categories of patient risk. The ‘pleiotropic’ effects of statins continue to reveal further potential benefits in a diverse range of interventional settings. The benefit of using statins acutely prior to scenarios where myocardial injury may be expected and in emergent situations is slowly being realised. The potential benefits of limiting myocardial injury in these settings are evident and further work is
References (118)
- et al.
Preoperative statin use and outcomes following cardiac surgery
Int J Cardiol
(2005) - et al.
Beneficial effects of pravastatin (+/− cholestyramine/niacin) initiated immediately after a coronary event (the randomised lipid coronary artery disease [L-CAD] study)
Am J Cardiol
(2000) - et al.
Effect of lipid lowering therapy on early mortality after acute coronary syndromes: an observational study
Lancet
(2001) - et al.
Relation of statin therapy to risk of heart failure after acute myocardial infarction
Am J Cardiol
(2008) - et al.
Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway
J Am Coll Cardiol
(2003) - et al.
Statins inhibit reoxygenation-induced cardiomyocyte apoptosis: role for glycogen synthase kinase 3 beta and transcription factor beta-catenin
J Mol Cell Cardiol
(2004) - et al.
Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty
J Am Coll Cardiol
(1997) - et al.
Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy)
Am J Cardiol
(2006) - et al.
Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality
J Am Coll Cardiol
(2002) - et al.
Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery
Ann Thorac Surg
(2007)
Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction
Am J Cardiol
Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection
Int J Biochem Cell Biol
Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial
J Vasc Surg
Statin therapy improves outcomes after valvular heart surgery
Ann Thorac Surg
Intensity of statin therapy in relation to myocardial ischemia, troponin T release, and clinical cardiac outcome in patients undergoing major vascular surgery
J Am Coll Cardiol
Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality
Am J Cardiol
Preconditioning and postconditioning: united at reperfusion
Pharmacol Ther
Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase
Am Heart J
Cardiac troponin T elevation after coronary artery bypass grafting is associated with increased one-year mortality
Am J Cardiol
A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery
Eur J Vasc Endovasc Surg
Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase
J Biol Chem
Pretreatment with statins enhances myocardial protection during coronary revascularization
J Thorac Cardiovasc Surg
Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?
J Am Coll Cardiol
Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention
Am J Cardiol
A study comparing the incidence and predictors of creatine kinase MB and troponin T release after coronary angioplasty. Does Clopidogrel preloading reduce myocardial necrosis following elective percutaneous coronary intervention?
Int J Cardiol
Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Results of the ARMYDA-ACS randomised trial
J Am Coll Cardiol
Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat
J Mol Cell Cardiol
The potential relevance of the multiple lipid-independent (pleotropic) effects of statins in the managment of acute coronary syndromes
J Am Coll Cardiol
Troponin I elevation and cardiac events after percutaneous coronary intervention
Am Heart J
Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: rationale and design of the DECREASE-IV study
Am Heart J
The cardioprotective effect of atorvastatin — is there a role for the adenosine receptor?
J Mol Cell Cardiol
Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy
Clin Ther
Early initiation of lipid lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial
Am Heart J
ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction
J Am Coll Cardiol
Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2
Am J Physiol Heart Circ Physiol
Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat
J Cardiovas Pharmacol Ther
Prostaglandins mediate the cardioprotective effects of atorvastatin against ischaemia-reperfusion injury
Cardiovasc Res
Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes — a meta-analysis of randomised controlled trials
JAMA
statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction
Eur Heart J
Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation
Am J Physiol Heart Circ Physiol
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
N Engl J Med
Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention
Circulation
Relation of inflammation and benefit of statins after percutaneous coronary interventions
Circulation
Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome
Catheter Cardiovasc Interv
Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome
Kardiol Pol
Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery
J Thorac Cardiovasc Surg
Relationship between postoperative cardiac troponin I levels and outcome of cardiac surgery
Circulation
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes — phase Z of the A to Z trial
J Am Med Assoc
Pravastatin in acute ischaemic syndromes: results of a randomised placebo-controlled trial
Int J Clin Pract
Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts
Cardiovasc Res
Cited by (159)
Myocardial ischemia-reperfusion injury and the influence of inflammation
2023, Trends in Cardiovascular MedicineSimvastatin attenuates the c-Raf/Erk and calcineurin-NFATc2 pathways via inhibition of Hsp90 activity during the development of heart failure
2023, Journal of Pharmacological SciencesThe Vascular System: Anatomical, Physiological, Pathological, and Aging Considerations
2022, Anesthesiology ClinicsSimvastatin-loaded sulfonated PEEK enhances angiogenesis and osteogenesis via miR-29cb2-mediated HIF-3α downregulation
2022, Chemical Engineering JournalStatins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
2021, Medical Hypotheses